This session is organized by Merck Serono
|Lunch session LS05, Thursday, April 19 2012, 12:30-14:o0, Room 2|
|Chair: François Chappuis, Division of International and Humanitarian Medicine, Geneva University Hospital, Geneva, Switerland|
|Summary: Schistosomiasis, also called Bilharzia, remains one of the most prevalent parasitic diseases in developing countries. Schistosomiasis, in contrast to other diseases such as malaria and TB, does not reveal a high mortality but impacts the whole population by its devastating chronic conditions starting already in early childhood. After malaria, schistosomiasis is the most important tropical disease in terms of human morbidity with significant economic and public health consequences.
Schistosomiasis is a severe chronic inflammatory disease and is endemic in about 75 developing countries, infecting more than 200 million people, with more than 90% of them living in Africa. Of the infected patients, 20 million suffer severe consequences from the disease. The prevalence of schistosomiasis especially in children is very high, accounting for about 50% of the total infected population.
Control of schistosomiasis is based on preventive chemotherapy interventions targeting the entire at-risk population using annual single oral dose of the drug Praziquantel. With the WHO Roadmap 2012 on “Accelerating work to overcome the global impact of neglected tropical diseases” and the increased praziquantel donation commitment from Merck KGaA, control and elimination of this chronic disease becomes a realistic goal within the next decade.
A group of renowned experts will first present their views on present and future strategies to tackle that challenge, and the audience will be invited to ask questions or comment on the proposed strategies. Announcement brochure
|Alan Fenwick, Imperial College London, Schistosomiasis Control Initiative, London, UK|
|Lorenzo Savioli, WHO-NTD, Geneva|
|Narcis Kabatareine, Vector Control Division, Ministry of Health, Uganda|
|Ton Polderman, Center of Infectious Diseases – LUMC, NL|
|Charles King, Center for Global Health and Diseases - Case Western Reserve University, US|